FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310119479> ?p ?o ?g. }

• W4310119479 endingPage "9316" @default.
• W4310119479 startingPage "9314" @default.
• W4310119479 abstract "Background Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that accounts for 50-75% of childhood cancers in sub-Saharan Africa. Recurrent infection with Plasmodium (P.) falciparum is hypothesized to be causally linked to BL, but the epidemiological evidence is limited because it is based on exposures measured after BL onset. The prolonged period before BL onset makes traditional cohort studies impractical. To circumvent this problem, it was proposed that genetic variants that confer genetic resistance to P falciparum, such as heterozygotes for the HBB sickle allele (rs334), could be used to demonstrate a causal link with malaria. However, results from six studies have been conflicting, perhaps, reflecting effects of small sample size, design flaws in the studies or confounding. For example, co-inheritance with other genetic variants, such as a-thalassemia, have been reported to confound the epidemiological associations of severe malaria with rs334. Additionally, resistance against P. falciparum due to premunition, defined as anti-clinical and anti-parasite resistance due to acquired immunity, could confound genetic associations with BL. To address the hypothesis of whether resistance to malaria protects against BL, we investigated the associations between BL and rs334 and 31 other single nucleotide polymorphisms (SNPs) plus α-thalassemia (hereafter, index malaria resistance SNPs/variants), and premunition, defined as P. falciparum positivity at enrollment, in cases enrolled in Uganda, Tanzania, Kenya, and Malawi, all designated as high malaria burden countries by the World Health Organization. Methods The study cohort consisted of 800 children (<16 years) with BL and 3845 children without BL enrolled in the Epidemiology of Burkitt Lymphoma in East African Children and Minors (EMBLEM) study (2010-2016) and the Infections and Childhood Cancer case-control study conducted in Malawi (2005-2010). P falciparum status was determined by thick-film microscopy, malaria antigen (HRP2/pLDH) rapid diagnostic test, or PCR at enrollment. Malaria protective SNPs were extracted from genome-wide data measured using Infinium Omni5Exome-4 v1.3 BeadChip (Illumina, San Diego, CA, USA). Genotyping for α3.7-thalassemia deletions (/-α3.7)utilized droplet digital polymerase chain reaction. We tested for associations between BL and the malaria index SNPs, a genotypes, and P. falciparum positivity using generalized linear mixed models, controlling for age, sex, and the first 3 population-specific principal components as fixed effects and for genetic relatedness (calculated from genome-wide data) as a random effect. We considered a p-value < 0.05 for statistical significance for malaria index SNPs. Results The mean age was similar for BL cases and controls (7.19 years versus 7.43 years, p= 0.07), but BL cases were more likely to be males (63.2% versus 52.1%, p£0.0001). P. falciparum positivity was lower in BL cases than controls (35.2% versus 48.3%, p<0.0001). Figure 1 shows the associations between 32 malaria index SNPs with BL and with P. falciparum positivity. Odds of BL were significantly decreased in presence of HBB rs334 (odds ratio [OR]= 0·687, 95% CI 0·533-0·885; p=0·0037) and ABO rs8176703 (0·591, 0·379-0·922; p=0.0203). Results for α-genotypes included the normal genotype (αα/αα), triplication (ααα/αα), -α3.7/αα, -α3.7/-α3.7deletions and unknown. Using αα/αα as the reference, the ORs for BL were 1.82, p=0.06 for ααα/αα; 1.07, p=0.469 for -α3.7/αα; and 0.78, p=0.15 for -α3.7/-α3.7. The odds of BL were significantly decreased with P. falciparum positivity in analyses without the two significant index SNPs (OR= 0.526, 95% CI 0.428-0.633, p=9.64x10-12) and changed minimally when the two SNPs were included (OR= 0·524, 0·435-0·630, p=7·291x10-12) . Conclusion Based on 4,581 children in four high malaria burden countries, we found reduced odds of BL among carriers of malaria index variants in HBB and ABO genes which suggests that these variants may protect against BL as well. Additionally, our findings of decreased odds of BL with P. falciparum positivity at enrollment suggest premunition may be protective against BL, independent of the significant associations with SNPs in HBB and ABO. Together, our findings further enhance the evidence of a causal role of malaria in BL; coordination between malaria and BL programs in countries with high malaria/BL burden should be strengthened. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310119479 created "2022-11-30" @default.
• W4310119479 creator A5001234632 @default.
• W4310119479 creator A5001416071 @default.
• W4310119479 creator A5003116913 @default.
• W4310119479 creator A5004872337 @default.
• W4310119479 creator A5006242858 @default.
• W4310119479 creator A5007262341 @default.
• W4310119479 creator A5008285050 @default.
• W4310119479 creator A5009724115 @default.
• W4310119479 creator A5012911692 @default.
• W4310119479 creator A5015384894 @default.
• W4310119479 creator A5026070019 @default.
• W4310119479 creator A5026241077 @default.
• W4310119479 creator A5027394490 @default.
• W4310119479 creator A5033056038 @default.
• W4310119479 creator A5035777125 @default.
• W4310119479 creator A5037297600 @default.
• W4310119479 creator A5037999627 @default.
• W4310119479 creator A5038965916 @default.
• W4310119479 creator A5039411132 @default.
• W4310119479 creator A5040404400 @default.
• W4310119479 creator A5040594895 @default.
• W4310119479 creator A5042138962 @default.
• W4310119479 creator A5046890585 @default.
• W4310119479 creator A5055620187 @default.
• W4310119479 creator A5058264242 @default.
• W4310119479 creator A5060496937 @default.
• W4310119479 creator A5061065833 @default.
• W4310119479 creator A5062973431 @default.
• W4310119479 creator A5065940853 @default.
• W4310119479 creator A5066699228 @default.
• W4310119479 creator A5066941080 @default.
• W4310119479 creator A5067533895 @default.
• W4310119479 creator A5067759844 @default.
• W4310119479 creator A5071099601 @default.
• W4310119479 creator A5071205750 @default.
• W4310119479 creator A5071689508 @default.
• W4310119479 creator A5074672054 @default.
• W4310119479 creator A5076081716 @default.
• W4310119479 creator A5077121960 @default.
• W4310119479 creator A5082156264 @default.
• W4310119479 creator A5082714424 @default.
• W4310119479 creator A5083164199 @default.
• W4310119479 creator A5083621501 @default.
• W4310119479 creator A5084148580 @default.
• W4310119479 creator A5085788179 @default.
• W4310119479 creator A5086799366 @default.
• W4310119479 creator A5087810640 @default.
• W4310119479 creator A5088697436 @default.
• W4310119479 creator A5091653870 @default.
• W4310119479 creator A5091806880 @default.
• W4310119479 date "2022-11-15" @default.
• W4310119479 modified "2023-10-18" @default.
• W4310119479 title "<i>HBB rs334</i>, <i>ABO R</i> <i>s8176703</i> and <i>Plasmodium Falciparum</i> Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi" @default.
• W4310119479 doi "https://doi.org/10.1182/blood-2022-170410" @default.
• W4310119479 hasPublicationYear "2022" @default.
• W4310119479 type Work @default.
• W4310119479 citedByCount "1" @default.
• W4310119479 countsByYear W43101194792023 @default.
• W4310119479 crossrefType "journal-article" @default.
• W4310119479 hasAuthorship W4310119479A5001234632 @default.
• W4310119479 hasAuthorship W4310119479A5001416071 @default.
• W4310119479 hasAuthorship W4310119479A5003116913 @default.
• W4310119479 hasAuthorship W4310119479A5004872337 @default.
• W4310119479 hasAuthorship W4310119479A5006242858 @default.
• W4310119479 hasAuthorship W4310119479A5007262341 @default.
• W4310119479 hasAuthorship W4310119479A5008285050 @default.
• W4310119479 hasAuthorship W4310119479A5009724115 @default.
• W4310119479 hasAuthorship W4310119479A5012911692 @default.
• W4310119479 hasAuthorship W4310119479A5015384894 @default.
• W4310119479 hasAuthorship W4310119479A5026070019 @default.
• W4310119479 hasAuthorship W4310119479A5026241077 @default.
• W4310119479 hasAuthorship W4310119479A5027394490 @default.
• W4310119479 hasAuthorship W4310119479A5033056038 @default.
• W4310119479 hasAuthorship W4310119479A5035777125 @default.
• W4310119479 hasAuthorship W4310119479A5037297600 @default.
• W4310119479 hasAuthorship W4310119479A5037999627 @default.
• W4310119479 hasAuthorship W4310119479A5038965916 @default.
• W4310119479 hasAuthorship W4310119479A5039411132 @default.
• W4310119479 hasAuthorship W4310119479A5040404400 @default.
• W4310119479 hasAuthorship W4310119479A5040594895 @default.
• W4310119479 hasAuthorship W4310119479A5042138962 @default.
• W4310119479 hasAuthorship W4310119479A5046890585 @default.
• W4310119479 hasAuthorship W4310119479A5055620187 @default.
• W4310119479 hasAuthorship W4310119479A5058264242 @default.
• W4310119479 hasAuthorship W4310119479A5060496937 @default.
• W4310119479 hasAuthorship W4310119479A5061065833 @default.
• W4310119479 hasAuthorship W4310119479A5062973431 @default.
• W4310119479 hasAuthorship W4310119479A5065940853 @default.
• W4310119479 hasAuthorship W4310119479A5066699228 @default.
• W4310119479 hasAuthorship W4310119479A5066941080 @default.
• W4310119479 hasAuthorship W4310119479A5067533895 @default.
• W4310119479 hasAuthorship W4310119479A5067759844 @default.
• W4310119479 hasAuthorship W4310119479A5071099601 @default.
• W4310119479 hasAuthorship W4310119479A5071205750 @default.
• W4310119479 hasAuthorship W4310119479A5071689508 @default.
• W4310119479 hasAuthorship W4310119479A5074672054 @default.

• next